Jang et al. [27] demonstrated that endogenous plasmalogens protect against hepatic steatosis and NASH by enhancing fatty acid oxidation through a PPARα-dependent mechanism, while Liu et al. [28] showed that plasmalogen supplementation can reduce hepatic steatosis in mouse models of obesity. Here, PPARA is linked to fatty liver disease.